Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
AGXT
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LUMASIRAN | ? unclear | Mechanistic | DGIdb | |
| NEDOSIRAN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL5173536 | ↓ inhibits | Mechanistic | 5600.0 nM (IC50) | ChEMBL |
| CHEMBL3764504 | ↓ inhibits | Mechanistic | 2400.0 nM (IC50) | ChEMBL |
| CHEMBL3765807 | ↓ inhibits | Mechanistic | 700.0 nM (IC50) | ChEMBL |
| CHEMBL3764222 | ↓ inhibits | Mechanistic | 1400.0 nM (IC50) | ChEMBL |
| CHEMBL3764351 | ↓ inhibits | Mechanistic | 160.0 nM (IC50) | ChEMBL |
| CHEMBL3763469 | ↓ inhibits | Mechanistic | 120.0 nM (IC50) | ChEMBL |
| CHEMBL3765396 | ↓ inhibits | Mechanistic | 300.0 nM (IC50) | ChEMBL |
| CHEMBL3764023 | ↓ inhibits | Mechanistic | 60.0 nM (IC50) | ChEMBL |
| CHEMBL3765186 | ↓ inhibits | Mechanistic | 300.0 nM (IC50) | ChEMBL |
| CHEMBL5179589 | ↓ inhibits | Mechanistic | 160.0 nM (IC50) | ChEMBL |
| CHEMBL3763498 | ↓ inhibits | Mechanistic | 200.0 nM (IC50) | ChEMBL |
| CHEMBL5170947 | ↓ inhibits | Mechanistic | 40.0 nM (IC50) | ChEMBL |
| CHEMBL5189330 | ↓ inhibits | Mechanistic | 850.0 nM (IC50) | ChEMBL |
| CHEMBL5204588 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL5207016 | ↓ inhibits | Mechanistic | 4600.0 nM (IC50) | ChEMBL |
| CHEMBL5207596 | ↓ inhibits | Mechanistic | 230.0 nM (IC50) | ChEMBL |
| CHEMBL5199538 | ↓ inhibits | Mechanistic | 550.0 nM (IC50) | ChEMBL |
| CHEMBL5183689 | ↓ inhibits | Mechanistic | 280.0 nM (IC50) | ChEMBL |
| CHEMBL5207995 | ↓ inhibits | Mechanistic | 230.0 nM (IC50) | ChEMBL |
| CHEMBL5181500 | ↓ inhibits | Mechanistic | 350.0 nM (IC50) | ChEMBL |
| CHEMBL5195123 | ↓ inhibits | Mechanistic | 620.0 nM (IC50) | ChEMBL |
CASR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| COMPOUND 18C [PMID:19143533] | ~ modulates | Mechanistic | DGIdb | |
| NPS 2143 | ~ modulates | Mechanistic | DGIdb | |
| D VITAMIN | ? unclear | Mechanistic | DGIdb | |
| AMINOGLYCOSIDE ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| TECALCET | ~ modulates | Mechanistic | DGIdb | |
| CINACALCET | ~ modulates | Mechanistic | DGIdb | |
| ETELCALCETIDE | ↑ activates | Mechanistic | DGIdb | |
| AXT-914 | ? unclear | Mechanistic | DGIdb | |
| TECALCET HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| NANOBODY NB32 | ~ modulates | Mechanistic | DGIdb | |
| NANOBODY NB4 | ~ modulates | Mechanistic | DGIdb | |
| ATF-936 | ? unclear | Mechanistic | DGIdb | |
| RONACALERET | ~ modulates | Mechanistic | DGIdb | |
| EVOCALCET | ~ modulates | Mechanistic | DGIdb | |
| AC265347 | ~ modulates | Mechanistic | DGIdb | |
| CALHEX 231 | ~ modulates | Mechanistic | DGIdb | |
| AXT914 | ~ modulates | Mechanistic | DGIdb | |
| ATF936 | ~ modulates | Mechanistic | DGIdb | |
| NPS-2143 | ? unclear | Mechanistic | DGIdb | |
| ENCALERET | ~ modulates | Mechanistic | DGIdb | |
| GOSICALCETIDE | ↑ activates | Mechanistic | DGIdb | |
| ASP7991 | ~ modulates | Mechanistic | DGIdb | |
| ETELCALCETIDE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| ENCALERET SULFATE | ? unclear | Mechanistic | DGIdb | |
| CINACALCET HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| (R)-2H [PMID:19625189] | ~ modulates | Mechanistic | DGIdb | |
| STRONTIUM RANELATE | ? unclear | Mechanistic | DGIdb | |
| 2-METHYL-3-PHENETHYL-3H-PYRIMIDIN-4-ONE | ↓ inhibits | Mechanistic | DGIdb | |
| SPERMINE | ↑ activates | Mechanistic | DGIdb | |
| PARATHYROID HORMONE | ? unclear | Mechanistic | DGIdb | |
| COMPOUND (S)-3H [PMID: 15686947] | ↓ inhibits | Mechanistic | DGIdb | |
| PAMIDRONATE DISODIUM | ? unclear | Mechanistic | DGIdb | |
| TRYPTOPHAN | ~ modulates | Mechanistic | DGIdb | |
| UPACICALCET | ~ modulates | Mechanistic | DGIdb | |
| CA2+ | ↑ activates | Mechanistic | DGIdb | |
| SB-423562 | ~ modulates | Mechanistic | DGIdb | |
| CALINDOL | ~ modulates | Mechanistic | DGIdb |
HAO1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LUMASIRAN SODIUM | ? unclear | Mechanistic | Open Targets | |
| LUMASIRAN | ? unclear | Mechanistic | Open Targets | |
| CHEMBL18672 | ↓ inhibits | Mechanistic | 440.0 nM (IC50) | ChEMBL |
| CHEMBL417634 | ↓ inhibits | Mechanistic | 3000.0 nM (IC50) | ChEMBL |
| CHEMBL18773 | ↓ inhibits | Mechanistic | 1400.0 nM (IC50) | ChEMBL |
| CHEMBL275811 | ↓ inhibits | Mechanistic | 19000.0 nM (IC50) | ChEMBL |
| CHEMBL18721 | ↓ inhibits | Mechanistic | 160.0 nM (IC50) | ChEMBL |
| CHEMBL276330 | ↓ inhibits | Mechanistic | 180.0 nM (IC50) | ChEMBL |
| CHEMBL428525 | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHEMBL282504 | ↓ inhibits | Mechanistic | 63.0 nM (IC50) | ChEMBL |
| CHEMBL19028 | ↓ inhibits | Mechanistic | 2100.0 nM (IC50) | ChEMBL |
| CHEMBL282502 | ↓ inhibits | Mechanistic | 600.0 nM (IC50) | ChEMBL |
| CHEMBL19036 | ↓ inhibits | Mechanistic | 400.0 nM (IC50) | ChEMBL |
| CHEMBL279530 | ↓ inhibits | Mechanistic | 1400.0 nM (IC50) | ChEMBL |
| CHEMBL274003 | ↓ inhibits | Mechanistic | 1100.0 nM (IC50) | ChEMBL |
| CHEMBL273783 | ↓ inhibits | Mechanistic | 90.0 nM (IC50) | ChEMBL |
| CHEMBL18295 | ↓ inhibits | Mechanistic | 60.0 nM (IC50) | ChEMBL |
| CHEMBL1229989 | ↓ inhibits | Mechanistic | 15.0 nM (Ki) | ChEMBL |
| CHEMBL4857427 | ↓ inhibits | Mechanistic | 6.7 nM (IC50) | ChEMBL |
| CHEMBL4864519 | ↓ inhibits | Mechanistic | 4.7 nM (IC50) | ChEMBL |
| CHEMBL4873879 | ↓ inhibits | Mechanistic | 11.0 nM (IC50) | ChEMBL |
| CHEMBL4855986 | ↓ inhibits | Mechanistic | 0.9 nM (IC50) | ChEMBL |
| CHEMBL4850573 | ↓ inhibits | Mechanistic | 1.2 nM (IC50) | ChEMBL |
| CHEMBL4861379 | ↓ inhibits | Mechanistic | 1.1 nM (IC50) | ChEMBL |
| CHEMBL4847068 | ↓ inhibits | Mechanistic | 3.6 nM (IC50) | ChEMBL |
| CHEMBL5094308 | ↓ inhibits | Mechanistic | 4000.0 nM (IC50) | ChEMBL |
| CHEMBL5093315 | ↓ inhibits | Mechanistic | 4400.0 nM (IC50) | ChEMBL |
| CHEMBL5075677 | ↓ inhibits | Mechanistic | 12000.0 nM (IC50) | ChEMBL |
| CHEMBL5081182 | ↓ inhibits | Mechanistic | 37.0 nM (IC50) | ChEMBL |
| CHEMBL5093622 | ↓ inhibits | Mechanistic | 22000.0 nM (IC50) | ChEMBL |
| CHEMBL5070808 | ↓ inhibits | Mechanistic | 17000.0 nM (IC50) | ChEMBL |
| CHEMBL5092972 | ↓ inhibits | Mechanistic | 11000.0 nM (IC50) | ChEMBL |
| CHEMBL5088254 | ↓ inhibits | Mechanistic | 4200.0 nM (IC50) | ChEMBL |
| CHEMBL5094641 | ↓ inhibits | Mechanistic | 2100.0 nM (IC50) | ChEMBL |
| CHEMBL5075215 | ↓ inhibits | Mechanistic | 170.0 nM (IC50) | ChEMBL |
| CHEMBL5080981 | ↓ inhibits | Mechanistic | 180.0 nM (IC50) | ChEMBL |
| CHEMBL5086346 | ↓ inhibits | Mechanistic | 21.0 nM (IC50) | ChEMBL |
| CHEMBL5077149 | ↓ inhibits | Mechanistic | 47.0 nM (IC50) | ChEMBL |
| CHEMBL5085053 | ↓ inhibits | Mechanistic | 860.0 nM (IC50) | ChEMBL |
| CHEMBL5079471 | ↓ inhibits | Mechanistic | 87.0 nM (IC50) | ChEMBL |
Showing top 40 of 177 agents ranked by evidence tier.
LDHA
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL:CHEMBL2058994 | ? unclear | Mechanistic | DGIdb | |
| ANTHRACYCLINE ANTINEOPLASTIC ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| NEDOSIRAN SODIUM | ? unclear | Mechanistic | Open Targets | |
| CHEMBL127326 | ↓ inhibits | Mechanistic | 1000.0 nM (Ki) | ChEMBL |
| CHEMBL435995 | ↓ inhibits | Mechanistic | 8000.0 nM (Ki) | ChEMBL |
| CHEMBL127327 | ↓ inhibits | Mechanistic | 6000.0 nM (Ki) | ChEMBL |
| CHEMBL338325 | ↓ inhibits | Mechanistic | 100.0 nM (Ki) | ChEMBL |
| CHEMBL127334 | ↓ inhibits | Mechanistic | 13000.0 nM (Ki) | ChEMBL |
| CHEMBL126519 | ↓ inhibits | Mechanistic | 300.0 nM (Ki) | ChEMBL |
| CHEMBL127645 | ↓ inhibits | Mechanistic | 22000.0 nM (Ki) | ChEMBL |
| CHEMBL310405 | ↓ inhibits | Mechanistic | 2000.0 nM (Ki) | ChEMBL |
| CHEMBL341463 | ↓ inhibits | Mechanistic | 700.0 nM (Ki) | ChEMBL |
| CHEMBL338262 | ↓ inhibits | Mechanistic | 200.0 nM (Ki) | ChEMBL |
| CHEMBL1232960 | ↓ inhibits | Mechanistic | 54000.0 nM (IC50) | ChEMBL |
| CHEMBL1232973 | ↓ inhibits | Mechanistic | 10000.0 nM (IC50) | ChEMBL |
| CHEMBL1688788 | ↓ inhibits | Mechanistic | 10400.0 nM (Ki) | ChEMBL |
| CHEMBL1688789 | ↓ inhibits | Mechanistic | 19800.0 nM (Ki) | ChEMBL |
| CHEMBL1688790 | ↓ inhibits | Mechanistic | 8900.0 nM (Ki) | ChEMBL |
| CARBOXYNAPHTHOL | ↓ inhibits | Mechanistic | 640000.0 nM (Kd) | ChEMBL |
| ADENOSINE PHOSPHATE | ↓ inhibits | Mechanistic | 650000.0 nM (Kd) | ChEMBL |
| CHEMBL2058993 | ↓ inhibits | Mechanistic | 4000000.0 nM (Kd) | ChEMBL |
| CHEMBL2058995 | ↓ inhibits | Mechanistic | 300000.0 nM (Kd) | ChEMBL |
| CHEMBL83103 | ↓ inhibits | Mechanistic | 1400000.0 nM (Kd) | ChEMBL |
| CHEMBL2058996 | ↓ inhibits | Mechanistic | 2400000.0 nM (Kd) | ChEMBL |
| CHEMBL2058997 | ↓ inhibits | Mechanistic | 1000000.0 nM (Kd) | ChEMBL |
| CHEMBL2058998 | ↓ inhibits | Mechanistic | 400000.0 nM (Kd) | ChEMBL |
| CHEMBL486329 | ↓ inhibits | Mechanistic | 4200000.0 nM (Kd) | ChEMBL |
| CHEMBL2058999 | ↓ inhibits | Mechanistic | 540000.0 nM (Kd) | ChEMBL |
| CHEMBL2059000 | ↓ inhibits | Mechanistic | 92000.0 nM (Kd) | ChEMBL |
| CHEMBL2059001 | ↓ inhibits | Mechanistic | 170000.0 nM (Kd) | ChEMBL |
| CHEMBL2059002 | ↓ inhibits | Mechanistic | 470000.0 nM (Kd) | ChEMBL |
| CHEMBL2059003 | ↓ inhibits | Mechanistic | 1000000.0 nM (Kd) | ChEMBL |
| CHEMBL2059007 | ↓ inhibits | Mechanistic | 240000.0 nM (Kd) | ChEMBL |
| CHEMBL2058994 | ↓ inhibits | Mechanistic | 12800.0 nM (Kd) | ChEMBL |
| CHEMBL578106 | ↓ inhibits | Mechanistic | 790000.0 nM (Kd) | ChEMBL |
| CHEMBL2059004 | ↓ inhibits | Mechanistic | 770000.0 nM (Kd) | ChEMBL |
| CHEMBL2059005 | ↓ inhibits | Mechanistic | 35000.0 nM (Kd) | ChEMBL |
| CHEMBL2059006 | ↓ inhibits | Mechanistic | 160000.0 nM (Kd) | ChEMBL |
| CHEMBL2059008 | ↓ inhibits | Mechanistic | 130.0 nM (Kd) | ChEMBL |
| CHEMBL2059009 | ↓ inhibits | Mechanistic | 46.0 nM (Kd) | ChEMBL |
Showing top 40 of 138 agents ranked by evidence tier.
SLC12A3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| POLYTHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CHLORTHALIDONE | ↓ inhibits | Mechanistic | DGIdb | |
| BENDROFLUMETHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| BENZTHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOTHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| HYDROFLUMETHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| QUINETHAZONE | ↓ inhibits | Mechanistic | DGIdb | |
| TORSEMIDE | ? unclear | Mechanistic | DGIdb | |
| CHLOROTHIAZIDE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| FUROSEMIDE | ? unclear | Mechanistic | DGIdb | |
| METHYCLOTHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DIAZOXIDE | ? unclear | Mechanistic | DGIdb | |
| TRICHLORMETHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| INDAPAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| BUMETANIDE | ? unclear | Mechanistic | DGIdb | |
| CHLOROTHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ↓ inhibits | Mechanistic | DGIdb | |
| METOLAZONE | ↓ inhibits | Mechanistic | DGIdb |
SLC22A12
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SHR-4640 | ↓ inhibits | Mechanistic | DGIdb | |
| LOSARTAN POTASSIUM | ? unclear | Mechanistic | DGIdb | |
| BENZBROMARONE | ↓ inhibits | Mechanistic | DGIdb | |
| CYTARABINE | ? unclear | Mechanistic | DGIdb | |
| ARHALOFENATE | ↓ inhibits | Mechanistic | DGIdb | |
| LESINURAD | ↓ inhibits | Mechanistic | DGIdb | |
| SULFINPYRAZONE | ↓ inhibits | Mechanistic | DGIdb | |
| DOTINURAD | ↓ inhibits | Mechanistic | DGIdb | |
| IDARUBICIN | ? unclear | Mechanistic | DGIdb | |
| GEMTUZUMAB OZOGAMICIN | ? unclear | Mechanistic | DGIdb | |
| FLUDARABINE | ? unclear | Mechanistic | DGIdb | |
| VERINURAD | ↓ inhibits | Mechanistic | DGIdb | |
| PRATOSARTAN | ↓ inhibits | Mechanistic | DGIdb |
SLC2A9
Pipeline results not yet available for this target. Run the pipeline to populate.
SLC34A1
Pipeline results not yet available for this target. Run the pipeline to populate.
SLC3A1
Pipeline results not yet available for this target. Run the pipeline to populate.
SLC7A9
Pipeline results not yet available for this target. Run the pipeline to populate.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| HYPOXANTHINE | ? unclear | Mechanistic | DGIdb | |
| BENZODIAZEPINE | ? unclear | Mechanistic | DGIdb | |
| CARVEDILOL | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| QUERCETIN | ? unclear | Mechanistic | 3000.0 nM (IC50) | DGIdb |
| FENTANYL CITRATE | ? unclear | Mechanistic | DGIdb | |
| FEBUXOSTAT | ↓ inhibits | Mechanistic | 30.0 nM (IC50) | DGIdb |
| OXYPURINOL | ↓ inhibits | Mechanistic | 1000.0 nM (Ki) | DGIdb |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| MISONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| METHYLENE BLUE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| MITOMYCIN | ? unclear | Mechanistic | DGIdb | |
| MERCAPTOPURINE | ? unclear | Mechanistic | DGIdb | |
| RICIN | ? unclear | Mechanistic | DGIdb | |
| OTERACIL POTASSIUM | ? unclear | Mechanistic | DGIdb | |
| AZITHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| STREPTONIGRIN | ? unclear | Mechanistic | DGIdb | |
| ALLOPURINOL | ↓ inhibits | Mechanistic | 4200.0 nM (IC50) | DGIdb |
| DIDANOSINE | ? unclear | Mechanistic | DGIdb | |
| ALLOPURINOL SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| PAPAVERINE | ? unclear | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| VINCRISTINE | ? unclear | Mechanistic | DGIdb | |
| TOPIROXOSTAT | ↓ inhibits | Mechanistic | DGIdb | |
| CLARITHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| NITROFURANTOIN, MACROCRYSTALS | ? unclear | Mechanistic | DGIdb | |
| ERYTHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| THIOGUANINE | ? unclear | Mechanistic | 92420.0 nM (IC50) | DGIdb |
| BENDAZAC | ↓ inhibits | Mechanistic | DGIdb | |
| ROXITHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| FOSDENOPTERIN | ? unclear | Mechanistic | DGIdb | |
| DAUNORUBICIN LIPOSOMAL | ? unclear | Mechanistic | DGIdb | |
| TIGULIXOSTAT | ? unclear | Mechanistic | DGIdb | |
| IMMUNOTHERAPEUTIC AGENT | ? unclear | Mechanistic | DGIdb | |
| CHEMOPREVENTIVE AGENT | ? unclear | Mechanistic | DGIdb | |
| CURCUMIN | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT INTERFERON | ? unclear | Mechanistic | DGIdb | |
| CHEMBL87562 | ↓ inhibits | Mechanistic | 330.0 nM (Ki) | ChEMBL |
Showing top 40 of 189 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Kidney Stones (Nephrolithiasis): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
This open-label pilot study evaluates whether oral microbial transplant therapy can change urine factors associated with recurrent calcium-oxalate kidney stones. Adults with high urine calcium or high urine oxalate will receive antibiotic pretreatment followed by microbial capsules. Changes in 24-ho...
Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the e...
The aims of this study are to 1) Conduct a randomized clinical trial of selective versus empiric diet plus pharmacologic therapy in high-risk stone formers and 2) Determine adverse effects from, and adherence to selective and empiric strategies.
This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation. The research focuses on people who have had calcium-based kidney stones, i.e. calcium oxalate or calcium phosphate stones. Prev...
This randomized controlled clinical trial evaluated whether furosemide-assisted forced diuresis during flexible ureteroscopy reduced the residual fragment rate and improved stone clearance in patients with renal stones measuring up to 30 millimeters. Adult patients undergoing flexible ureteroscopy w...
This single-center randomized controlled trial at Mount Sinai West will enroll 80 patients undergoing percutaneous nephrolithotomy for calcium oxalate stones. Participants will be randomized to receive either empiric therapy or selective therapy guided by 24-hour urine evaluation. The primary outcom...
This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.
Percutaneous nephrolithotomy is a minimally invasive surgical procedure used to remove large kidney stones. Although it is an effective treatment, bleeding during and after the procedure remains one of the main concerns and may sometimes require blood transfusion. Tranexamic acid is a medication tha...
Extensive literature exists on the use of alpha-blocker medications for the removal of kidney stones. Alpha blockers relax certain muscles and help small blood vessels remain open. They work by keeping the hormone norepinephrine (noradrenaline) from tightening the muscles in the walls of smaller art...
This is a Phase 2a study of glycolate oxidase inhibitor LLX-424 in patients with a history of kidney stones. Eligible subjects with a history of kidney stones will be randomized to receive study drug (LLX-424 or placebo) for 8 weeks.
This study aims to evaluate whether the use of alpha-blockers before flexible ureterorenolithotripsy facilitates the passage of the ureteral access sheath. The trial will enroll adult patients diagnosed with kidney stones who are scheduled for flexible ureteroscopy. Participants will be randomly ass...
This is a randomized control trial comparing oral ketorolac and opioid medication for the use of post-operative analgesia.
This study will be a multi-institutional randomized clinical trial of a short course of pre-operative antibiotic prophylaxis in addition to perioperative antibiotics prior to undergoing percutaneous nephrolithotomy. The select patient population will be those patients deemed to be at a moderately in...
Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults. Hypercalciuria can be secondary to increased intestinal absorption and/or increased renal distal tubular re...
The investigators plan to assess the efficacy of standard and low dose HCTZ treatment in the recurrence prevention of calcium-containing kidney stones. More specifically, the investigators aim to assess the dose-response relationship for three different dosages of HCTZ. Study intervention: HCTZ 12.5...
Agents Found By Disease-Level Search
Searched directly from “Kidney Stones (Nephrolithiasis)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
41 agents shown (approved or with trial evidence) — 41 not found by the gene-target search above.
RIRSNOT in gene-target list
Flexible UreteroscopyNOT in gene-target list
PCNLNOT in gene-target list
Mini-percutaneous nephrolithotomyNOT in gene-target list
percutaneous nephrolithotomyNOT in gene-target list
mini-PCNLNOT in gene-target list
Percutaneous nephrolitotomyNOT in gene-target list
Ketorolac Trometamol 30Mg/1mL InjectionNOT in gene-target list
Neorenal ForteNOT in gene-target list
Extracorporeal Shock Wave Lithotripsy (ESWL)NOT in gene-target list
Furosemide-Fludrocortisone-Test (test for urinary acidification)NOT in gene-target list
ESWLNOT in gene-target list
Rigid and flexible ureteroscopeNOT in gene-target list
LithotripterNOT in gene-target list
Basket for fragment removalNOT in gene-target list
General or spinal anesthesiaNOT in gene-target list
Intravenous pain medicationNOT in gene-target list
CiprofloxacinNOT in gene-target list
Percutaneous nephrolithotomi (PCNL)NOT in gene-target list
NIRSNOT in gene-target list
Genetic analysisNOT in gene-target list
PramipexoleNOT in gene-target list
MorphineNOT in gene-target list
Flexible UreterorenoscopyNOT in gene-target list
laparoscopic pyelolithotomyNOT in gene-target list
Cone beam CTNOT in gene-target list
Marcaine Injectable ProductNOT in gene-target list
5mg Oxycodone, Q6 PRNNOT in gene-target list
10mg Ketorolac, Q6 PRNNOT in gene-target list
Hydroxycitrate (HCA)NOT in gene-target list
CannabidiolNOT in gene-target list
BupivacaineNOT in gene-target list
Aloe vera with cactusNOT in gene-target list
CranberryNOT in gene-target list
Green tea extractNOT in gene-target list
BilberryNOT in gene-target list
CinnamonNOT in gene-target list
Milk thistleNOT in gene-target list
TurmericNOT in gene-target list
Aloe veraNOT in gene-target list
TamsulosinNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.